Goldman Sachs raises its gold price target to $4,900 by end-2026
Tharimmune, Inc. (NASDAQ:THAR), currently trading at $3.99 with a market capitalization of $18.5 million, announced on Friday that its stockholders equity now exceeds the $2.5 million minimum required for continued listing on the Nasdaq Capital Market. According to InvestingPro data, the stock has shown significant volatility, with a 150% surge over the past six months despite recent pullbacks. The update follows two recent registered direct offerings and a private placement that raised a total of approximately $7.05 million in gross proceeds. InvestingPro analysis shows the company maintains a favorable cash position, holding more cash than debt on its balance sheet, though its overall financial health score remains weak.
According to a press release statement included in the company’s Form 8-K filed with the Securities and Exchange Commission, Tharimmune received a notice from Nasdaq on April 1 indicating that its stockholders equity, as reported in its annual report for the period ended December 31, 2024, was below the required threshold. The company submitted a compliance plan to Nasdaq on May 15.
On July 25, Tharimmune closed a registered direct offering of common stock and common stock equivalents, along with a concurrent private placement of warrants, for gross proceeds of about $1.7 million. An additional registered direct offering closed on August 27, raising approximately $5.35 million in gross proceeds. These capital raises come as the company faces profitability challenges, with analysts not anticipating positive earnings this year, according to InvestingPro forecasts.
As a result of these transactions, the company’s stockholders equity now exceeds the $2.5 million requirement. Tharimmune has provided an unaudited consolidated balance sheet as of August 31, 2025, as an exhibit to the filing.
The company’s common stock continues to trade on the Nasdaq Capital Market under the symbol THAR. The information in this article is based on a press release statement and the company’s SEC filing.
In other recent news, Tharimmune, Inc. announced a securities purchase agreement for a direct offering of approximately $5.35 million of its common stock. This offering involves issuing 1,188,888 shares at $4.50 each, as disclosed in a filing with the U.S. Securities and Exchange Commission. Tharimmune also reported positive results from a pharmacokinetic simulation analysis of its lead asset, TH104, a buccal film formulation of nalmefene, which could provide extended protection against respiratory depression from opioids. The company has expanded its intellectual property portfolio, securing new patents for its TH-104 technology in Japan, Mexico, Australia, and the United States, extending protection until at least 2040. Additionally, Tharimmune announced key leadership changes, appointing Sireesh Appajosyula as CEO, Vincent LoPriore as Executive Chairman, and James Gordon Liddy to the Board of Directors. These changes follow the resignation of Randy Milby from his roles as CEO and Board member. Under a settlement agreement, Milby will receive a payment upon the company securing a minimum of $3 million in financing.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.